Real-World Treatment Patterns, Tolerability, and Outcomes Among Patients With CLL/SLL Treated With First-Line Ibrutinib, Acalabrutinib, or Zanubrutinib in the US Community Oncology Setting: A Retrospective Cohort Study.
BTK inhibitors cause more patients to stop treatment in real practice than clinical trials show, highlighting a need for better-tolerated first-line leukemia drugs.
This retrospective EHR-based cohort of 584 CLL/SLL patients in US community oncology found cBTKi discontinuation occurred more frequently than in clinical trials (51.2% at 24 months), driven primarily by adverse events, with ibrutinib associated with shorter time to discontinuation versus acalabrutinib. The majority of patients who discontinued first-line BTK inhibitor therapy did not receive subsequent treatment, highlighting unmet need for more tolerable 1L strategies in community practice.
What the study was
- Study design
- retrospective_cohort
- Category
- hematologic_malignancies
- Maturity
- Validated
- Journal
- eJHaem
Why it surfaced
Real-world community oncology data demonstrates substantially higher BTKi discontinuation rates than clinical trials; directly informs treatment selection and monitoring strategies for first-line CLL.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.